Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Go back to Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs| (NASDAQ: PRAX) | Delayed: 303.39 +21.08 (7.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $282.31 | 52 Week High | $ | |||
| Open | $292.56 | 52 Week Low | $ | |||
| Day High | $305.00 | P/E | N/A | |||
| Day Low | $285.00 | EPS | $ | |||
| Volume | 657,226 | |||||
